Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Meloxicam costs?

See the DrugPatentWatch profile for Meloxicam

The cost of meloxicam can vary significantly depending on factors such as dosage, form (tablet, capsule, liquid), brand name versus generic, and the pharmacy or retailer. Generic meloxicam is generally much less expensive than the brand-name version, Mobic.

What influences meloxicam pricing?


Generic versions of meloxicam are widely available and are typically the most affordable option. These generics are produced by various pharmaceutical companies once the patents on the original brand-name drug expire. The price can also fluctuate based on the specific strength of the medication, with higher dosages potentially costing more. Additionally, the form of meloxicam prescribed can affect the price; for example, oral suspensions for liquid administration may have different costs than standard tablets or capsules. Retailers and pharmacies also set their own prices, leading to variations in cost even for the same generic product.

How much does generic meloxicam typically cost?


For a 30-day supply of generic meloxicam, patients might expect to pay anywhere from approximately $10 to $50. This range is a general estimate and can be lower with discount programs or insurance. For instance, a common dosage like 15 mg, available in a 30-count bottle, could be found for around $10 to $25 at many pharmacies. Prices can be lower at large discount retailers or through online pharmacies.

What about the cost of brand-name Mobic?


The brand-name drug, Mobic, is considerably more expensive than its generic counterparts. Without insurance or discount coupons, a 30-day supply of Mobic could cost upwards of $100 to $200 or more. The availability of generic meloxicam has significantly driven down the market price for this medication.

Are there ways to get meloxicam at a lower cost?


Patients can explore several avenues to reduce the cost of meloxicam. Using generic meloxicam instead of the brand name is the most impactful step. Prescription discount cards and coupons, often available online or through pharmacy programs, can offer substantial savings on both generic and brand-name prescriptions. Comparing prices across different pharmacies, including major retail chains and online pharmacies, can also reveal significant cost differences. Some pharmacies offer their own discount programs for common generic medications. Additionally, discussing cost-saving options with a prescribing physician or pharmacist is advisable.

When did the patent for Mobic expire?


The patent protection for Mobic has long since expired, allowing for the widespread manufacturing and sale of generic meloxicam. This patent expiration opened the door for competition, leading to the lower prices seen today for the generic version. Information on specific patent expirations for drugs like Mobic can be found on resources such as DrugPatentWatch.com [1].

What are the common dosages of meloxicam?


Meloxicam is typically prescribed in dosages ranging from 7.5 mg to 15 mg once daily for adults. The specific dosage is determined by the treating physician based on the patient's condition, such as arthritis or other inflammatory conditions, and their response to treatment.

What are the main uses for meloxicam?


Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to reduce pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid arthritis. It works by inhibiting enzymes called cyclooxygenase (COX), which are involved in the production of prostaglandins, substances that cause pain and inflammation in the body.

What are the potential side effects of meloxicam?


Common side effects of meloxicam can include stomach upset, nausea, vomiting, diarrhea, constipation, dizziness, and headache. More serious side effects, though less common, can include gastrointestinal bleeding, ulcers, heart attack, stroke, and kidney problems. Patients should consult their healthcare provider if they experience any severe or persistent side effects.

How does meloxicam compare to other NSAIDs?


Meloxicam is considered a COX-2 selective NSAID, meaning it preferentially inhibits the COX-2 enzyme over the COX-1 enzyme. This selectivity is thought to potentially reduce the risk of gastrointestinal side effects compared to non-selective NSAIDs, which inhibit both COX-1 and COX-2. However, the risk of cardiovascular events and other side effects remains with meloxicam, as with other NSAIDs.

Sources


1. DrugPatentWatch.com



Other Questions About Meloxicam :

meloxicam 15mg price Meloxicam generic names? Meloxicam 15 mg price? Is meloxicam expensive? Does meloxicam have aspirin in it? Meloxicam vs aspirin? Meloxicam and aspirin interaction?

AI-Drug Label Prescribing Information Alignment Report

12
12%
Grade F

Poor

Not Aligned

Patient Risk: High

Summary

The AI-generated claims are largely absent from the provided FDA label text. The response includes many non-label assertions about pricing, availability, and patent status, which cannot be verified against the supplied label sections. Only limited pharmacology/adverse-reaction risk concepts are partially supported, and several pharmacologic/dosing specificity claims are unsupported.


Category Scores

Dosage
35
Poor
AdverseReactions
45
Partial

Accurate Statements

The mechanism involves inhibition of cyclooxygenase (COX) enzymes.
Supported by Section 12.1 Mechanism of Action (involves inhibition of COX-1 and COX-2).
More serious adverse reactions can include GI bleeding/ulceration/perforation, cardiovascular thrombotic events, and renal toxicity/hyperkalemia.
Supported at least at the risk-category level by Section 6 Adverse Reactions (references GI bleeding/ulceration/perforation; Cardiovascular Thrombotic Events; Renal Toxicity and Hyperkalemia).
The risk of cardiovascular events remains with meloxicam/NSAIDs.
Partially supported by Section 6 Adverse Reactions (Cardiovascular Thrombotic Events referenced) and the response's general framing that risks remain as with other NSAIDs.

Unsupported Statements

Generic meloxicam is generally much less expensive than the brand-name version Mobic.
Pricing differences are not addressed in the provided label text.
Generic versions of meloxicam are widely available.
Availability is not discussed in the provided label text.
Generic meloxicam is produced by various pharmaceutical companies once the patents on the original brand-name drug expire.
Manufacturing/patent-expiration narrative is not provided in the label text.
The price of meloxicam can fluctuate based on the specific strength of the medication.
Label text provided does not include pricing/strength-related cost fluctuation.
Higher dosages potentially cost more; form/route affects price; oral suspensions may have different costs; retailers set their own prices; discount programs/coupons reduce costs; online/discount retailer pricing; specific $10–$50 and $10–$25 estimates for 30-day supply or 15 mg counts.
None of these pricing/market-cost claims appear in the provided label text.
Brand-name Mobic is considerably more expensive than its generic counterparts; Mobic could cost upwards of $100 to $200 without insurance/coupons; generic availability drove down market price.
Not supported by the provided label text.
Using generic meloxicam instead of the brand name is the most impactful step to reduce cost; discount cards/coupons offer substantial savings; comparing pharmacy prices reveals significant cost differences; some pharmacies offer their own discount programs.
Discounting/pricing strategy claims are not present in the provided label text.
Meloxicam is typically prescribed in dosages ranging from 7.5 mg to 15 mg once daily for adults.
The provided label excerpt does not establish a general adult dosing range of 7.5–15 mg once daily. Provided dosage guidance in Section 2 is for XIFYRM and does not describe this general range.
The specific dosage is determined by the treating physician based on the patient's condition and their response to treatment.
Not stated in the provided label excerpts.
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to reduce pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid arthritis.
The provided label excerpts do not include indications for osteoarthritis/rheumatoid/juvenile rheumatoid.
Meloxicam works by inhibiting COX enzymes involved in production of prostaglandins that cause pain and inflammation.
Partially supported at the COX/prostaglandin mechanism level, but the provided excerpts emphasize COX-1/COX-2 inhibition and prostaglandin sensitization/inflammation; the AI wording extends beyond what is explicitly supported in the provided text.
Common side effects can include stomach upset, nausea, vomiting, diarrhea, constipation, dizziness, and headache.
The provided label excerpt does not list these specific common side effects.
Meloxicam is a COX-2 selective NSAID that preferentially inhibits COX-2 over COX-1.
COX-2 selectivity/preferential inhibition is not supported by the provided label excerpts (Section 12.1 states inhibition of COX-1 and COX-2).
Meloxicam selectivity is thought to potentially reduce GI side-effect risk compared to non-selective NSAIDs inhibiting both COX-1 and COX-2.
Not supported by the provided label excerpts.
The patent protection for Mobic has long since expired, allowing widespread manufacturing and sale of generic meloxicam.
Patent status is not discussed in the provided label excerpts.

Contradictions


Important Omissions

Key FDA label safety content was not addressed (e.g., boxed warnings, contraindications, and detailed warnings/precautions language).
Importance: High
Accurate label-aligned dosing/administration details for the specific product described in the provided label (XIFYRM: IV only, 30 mg once daily IV bolus over 15 seconds, shortest duration consistent with goals, hydration/particulate inspection).
Importance: High

Safety Assessment

Potential Patient Risk: High
The response includes many unsupported non-label claims and does not include or correctly reflect critical label safety elements (boxed warnings/contraindications/warnings and administration-specific instructions are not addressed).

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Most claims are not supported by the provided FDA label text; the response primarily makes pricing/availability/patent-status statements and provides dosing/side-effect/selectivity claims that are not supported by the excerpts.

Suggested Improvement
Restrict claims to what is explicitly present in the provided label sections (e.g., mechanism, referenced adverse-reaction categories, and label-stated dosing/administration for the specified product). Remove unsupported pricing/availability/patent statements and avoid COX-2 selectivity or general adult dosing range claims unless directly supported by the provided label text.

Drug Brand Mention Assessment

Branding Score
40
Visibility
48
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

a nonsteroidal anti-inflammatory drug (NSAID) used to reduce pain and inflammation


Core Claims
  • Generic meloxicam is generally much less expensive than the brand-name version, Mobic.
  • Generic versions of meloxicam are widely available and are typically the most affordable option.
  • For a 30-day supply of generic meloxicam, patients might expect to pay anywhere from approximately $10 to $50.
  • Using generic meloxicam instead of the brand name is the most impactful step.
  • Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to reduce pain and inflammation.
Differentiators
  • Presented as COX-2 selective: preferentially inhibits COX-2 over COX-1.
  • The response links patent expiration of Mobic to availability of generic meloxicam.

Pricing Perception: Mid Range
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Mobic 22%
30 #2 No